Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting
Recombinant vaccinia virus with tumour cell specificity may provide a versatile tool either for direct lysis of cancer cells or for the targeted transfer of genes encoding immunomodulatory molecules. We report the expression of a single chain antibody on the surface of extracellular enveloped vaccinia virus. The wild-type haemagglutinin, an envelope glycoprotein which is not required for viral infection and replication, was replaced by haemagglutinin fusion molecules carrying a single chain antibody directed against the tumour-associated antigen ErbB2. ErbB2 is an epidermal growth factor receptor-related tyrosine kinase overexpressed in a high percentage of human adenocarcinomas. Two fusion proteins carrying the single chain antibody at different NH2-terminal positions were expressed and exposed at the envelope of the corresponding recombinant viruses. The construct containing the antibody at the site of the immunoglobulin-like loop of the haemagglutinin was able to bind solubilized ErbB2. This is the first report of replacement of a vaccinia virus envelope protein by a specific recognition structure and represents a first step towards modifying the host cell tropism of the virus.
AppleyardG., HapelA. J., BoulterE. A.1971; An antigenic difference between intracellular and extracellular rabbitpox virus. Journal of General Virology 3:9–17
BaselgaJ., TripathyD., MendelsohnJ., BaughmanS., BenzC. C., DantisL., SklarinN. T., SeidmanA. D., HudisC. A., MooreJ., RosenP. P., TwaddellT., HendersonI. C., NortonL.1996; Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Journal of Clinical Oncology 14:737–744
BodeyB., SiegelS. E., KaiserH. E.1996; Human cancer detection and immunotherapy with conjugated and nonconjugated monoclonal antibodies [Review]. Anticancer Research 16:661–674
ChuT. H., DornburgR.1995; Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. Journal of Virology 69:2659–2663
HanX., KasaharaN., KanY. W.1995; Ligand -directed retroviral targeting of human breast cancer cells. Proceedings of the National Academy of Sciences, USA 92:9747–9751
HarwerthI. M., WelsW., MarteB. M., HynesN. E.1992; Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists. Journal of Biological Chemistry 267:15160–15167
HodgeJ. W., AbramsS., SchlomJ., KantorJ. A.1994; Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Research 54:5552–5555
IchihashiY., MatsumotoS., DalesS.1971; Biogenesis of poxviruses : role of A-type inclusions and host cell membranes in virus dissemination. Virology 46:507–532
JinD. Y., LiZ. L., JinQ., HaoY. W., HouY. D.1989; Vaccinia virus hemagglutinin. A novel member of the immunoglobulin superfamily. Journal of Experimental Medicine 170:571–576
KatzE., WolffeE. J., MossB.1997; The cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions. Journal of Virology 71:3178–3187
LaiC. F., GongS. C., EstebanM.1991; The 32-kilodalton envelope protein of vaccinia virus synthesized in Escherichia coli binds with specificity to cell surfaces. Journal of Virology 65:499–504
LeeS. S., EisenlohrL. C., McCueP. A., MastrangeloM. J., LattimeE. C.1994; Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Research 54:3325–3328
MachJ. P., PelegrinA., BucheggerF.1991; Imaging and therapy with monoclonal antibodies in non-hematopoietic tumors [Review]. Current Opinion in Immunology 3:685–693
MackettM., SmithG. L., MossB.1982; Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proceedings of the National Academy of Sciences, USA 79:7415–7419
MarinM., NoelD., ValsesiawittmanS., BrocklyF., EtiennejulanM., RussellS., CossetF. L., PiechaczykM.1996; Targeted infection of human cells via major histocompatibility complex class I molecules by moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. Journal of Virology 70:2957–2962
McIntoshA. A., SmithG. L.1996; Vaccinia virus glycoprotein A34R is required for infectivity of extracellular enveloped virus. Journal of Virology 70:272–281
MoritzD., WelsW., MatternJ., GronerB.1994; Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB1-expressing tumor cells. Proceedings of the National Academy of Sciences, USA 91:4318–4322
PanicaliD., PaolettiE.1982; Construction of poxviruses as cloning vectors : insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proceedings of the National Academy of Sciences, USA 79:4927–4931
PayneL. G.1979; Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus. Journal of Virology 31:147–155
PayneL. G.1980; Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. Journal of General Virology 50:89–100
PayneL. G., KristenssonK.1985; Extracellular release of enveloped vaccinia virus from mouse nasal epithelial cells in vivo. Journal of General Virology 66:643–646
PeplinskiG. R., TsungK., MekoJ. B., NortonJ. A.1995; In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1β. Surgery 118:185–191
SomiaN. V., ZoppeM., VermaI. M.1995; Generation oftargeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene delivery. Proceedings of the National Academy of Sciences, USA 92:7570–7574
WelsW., HarwerthI. M., MuellerM., GronerB., HynesN. E.1992a; Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor. Cancer Research 52:6310–6317
WelsW., HarwerthI. M., ZwicklM., HardmanN., GronerB., HynesN. E.1992b; Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Bio/Technology 10:1128–1132
WelsW., BeerliR., HellmannP., SchmidtM., MarteB. M., KornilovaE. S., HekeleA., MendelsohnJ., GronerB., HynesN. E.1995; EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins. International Journal of Cancer 60:137–144
YardenY.1990; Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active. Proceedings of the National Academy of Sciences, USA 87:2569–2573
Expression of a functional single chain antibody on the surface of extracellular enveloped vaccinia virus as a step towards selective tumour cell targeting